FDA Inspection Defense Attorney: What to Do During and After an FDA Inspection
Many businesses do not call a lawyer until after an FDA inspection is over. By then, the record may already be set: investigator notes, management statements, document productions, facility photographs, employee interviews, and possibly a Form 483 on the way out the door.
That is why FDA inspection defense begins before the inspection ends. Whether the inspection is routine, risk-based, for-cause, or tied to a complaint, adverse event, import issue, website claim, or referral from another agency, the company is not simply “showing the facility.” It is participating in the creation of an enforcement file.
Why FDA inspections matter
FDA inspections are often the opening stage of a much larger problem. A single inspection can lead to a 483, a warning letter, a recall, import refusal, product hold, withheld approvals, civil litigation, or criminal scrutiny. In drug, biologic, device, compounding, regenerative-medicine, and telehealth matters, the inspection often determines how much leverage the agency will have later.
In short, inspections are evidence-gathering events. Smart companies treat them that way.
What FDA investigators usually focus on
The exact focus depends on the product and regulatory regime, but the pressure points are familiar:
- current good manufacturing practices,
- sterility and contamination controls,
- complaint files and adverse events,
- batch records and deviation investigations,
- data integrity,
- labeling and promotional claims,
- validation and change control,
- training and management oversight,
- sourcing and supplier qualification,
- prescription, compounding, or patient-specific requirements,
- website and social-media claims,
- records showing what leadership knew and when.
What matters legally is not just what investigators see. It is also what your people say while investigators are there.
What to do at the start of an FDA inspection
The first hour matters. A company should know who greets investigators, who checks credentials, who manages the inspection room, who serves as document coordinator, who sits in on interviews, and who communicates with counsel.
Basic discipline makes a difference:
- designate one internal inspection lead,
- funnel all document requests through one channel,
- log every request and production,
- avoid volunteer commentary,
- keep a contemporaneous company-side record of what is inspected,
- preserve copies of everything produced,
- separate facts from assumptions.
This is not about obstruction. It is about control, accuracy, and protecting the company from confusion that later looks like inconsistency.
Employee interviews and management statements
One of the most dangerous parts of an inspection is informal talking. Employees often try to be helpful and end up speculating, guessing, or adopting the investigator’s language without realizing the consequences.
The right approach is preparation, not performance. Employees should answer truthfully, stay within personal knowledge, avoid speculation, and understand when a question should be directed to a different subject-matter lead.
Management should be especially careful. Investigators will often test whether leadership understands the process, recognized the issue earlier, or failed to act on warning signs. Loose admissions can be more damaging than the underlying observation.
What happens after the inspection?
If investigators identify objectionable conditions, they may issue a Form FDA 483 at the close of the inspection. That is not the final word, but it is a serious development.
FDA then evaluates the inspection record, the 483, evidence collected on-site, and the company’s response. Depending on the outcome, the inspection can be classified in a way that allows voluntary correction or in a way that supports more formal action. In serious cases, FDA can move toward warning letters, import consequences, recalls, injunctions, seizures, or criminal referral.
That means the inspection defense strategy must continue after the investigators leave.
The best post-inspection playbook
A serious FDA inspection should trigger five immediate steps:
1. Preserve documents and communications
Do not let emails, texts, quality records, or website content disappear.
2. Conduct a privileged internal investigation
Counsel should help determine whether the issue is isolated or systemic.
3. Build a defensible corrective-action plan
Not a cosmetic fix. A real one.
4. Coordinate technical and legal messaging
Quality remediation and legal positioning have to match.
5. Prepare for reinspection and escalation
Anything promised today may be tested later.
Why Ronald W. Chapman II is well positioned for FDA inspection defense
Ronald W. Chapman II is not a generic regulatory lawyer writing from the sidelines. He is a federal defense attorney with a healthcare-regulatory background, an LL.M. in Health Care Law, and a practice focused on defending professionals and regulated organizations when government scrutiny threatens careers, licenses, businesses, and liberty.
He also understands how government cases are built. As a former federal prosecutor and U.S. Marine Corps Judge Advocate, he knows how investigators document cases and how prosecutors later use those records. His healthcare fraud victories and work defending providers and regulated entities in high-stakes matters give him unusual credibility when an inspection may overlap with allegations of fraud, adulteration, misbranding, false claims, or controlled-substance issues.
That mix of trial skill and regulatory fluency is especially important when an inspection cannot be treated as a purely technical quality event.
FAQ
Can a lawyer be involved during an FDA inspection?
Yes. In significant inspections, counsel should often be involved in real time or immediately afterward.
Is a routine inspection less dangerous?
Not necessarily. Routine inspections can uncover issues that become formal enforcement matters.
What if the inspection focused on website claims?
Then the matter may implicate marketing, intended use, misbranding, and evidence of management knowledge—not just facility procedures.
Call to action: If FDA is on-site or has just left your facility, early legal strategy can change what happens next.